Mitigating the burden of SARS-CoV-2 in at-risk populations with adapted COVID-19 vaccines

The webinar will explore how the burden of SARS-CoV-2 variants may be mitigated with adapted vaccines. It will delve into the current burden of SARS-CoV-2 variants and populations at risk, data on adapted vaccine efficacy and safety, and vaccination strategies.

Learning objectives

  1. Appraise surveillance data on dominant circulating influenza and SARS-CoV-2 strains to inform optimal vaccine composition beyond the pandemic period
  2. Discuss immunological considerations for optimized vaccine design against prevalent influenza and COVID strains
  3. Evaluate vaccine effectiveness data against emergent RID strains and strategies to enhance broad protective immunity against antigenic variants
  4. Examine vaccine platforms (e.g. mRNA) for rapid adaptation against evolving epitopes of RID pathogens

For more information, view the full agenda.

Meet Your Expert Panel

  • Luke Moore, Imperial College, Infectious Diseases, Microbiology, & Virology, London
  • Martina Prelog, University of Wuerzburg, Pediatric Rheumatology and Special Immunology
  • Albert Osterhaus, University of Veterinary Medicine Hannover, Germany 

These renowned experts will explore the burden of SARS-CoV-2 variants in populations at risk and discuss mitigation strategies using adapted vaccines.